MX2022006573A - Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias. - Google Patents

Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.

Info

Publication number
MX2022006573A
MX2022006573A MX2022006573A MX2022006573A MX2022006573A MX 2022006573 A MX2022006573 A MX 2022006573A MX 2022006573 A MX2022006573 A MX 2022006573A MX 2022006573 A MX2022006573 A MX 2022006573A MX 2022006573 A MX2022006573 A MX 2022006573A
Authority
MX
Mexico
Prior art keywords
methods
inflammatory diseases
treating inflammatory
spa
diseases
Prior art date
Application number
MX2022006573A
Other languages
English (en)
Inventor
Annette Bettina Galler
Steven John Padula
Matthias Arndt
Stella Aslanyan
Mary Ruth Flack
Bojan LALOVIC
Paul Russell SCHOLL
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022006573A publication Critical patent/MX2022006573A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a métodos para el tratamiento de enfermedades relacionadas con IL-23, en particular, enfermedades inflamatorias, tales como psoriasis, artritis psoriásica o espondiloartritis axial (espinal) (ax-SpA), que incluye la espondilitis anquilosante y la ax-SpA no radiográfica, que utilizan anticuerpos anti-IL-23A.
MX2022006573A 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias. MX2022006573A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562111731P 2015-02-04 2015-02-04
US201562130876P 2015-03-10 2015-03-10
US201562135335P 2015-03-19 2015-03-19
US201562145764P 2015-04-10 2015-04-10
US201562204520P 2015-08-13 2015-08-13
US201562235631P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
MX2022006573A true MX2022006573A (es) 2022-07-11

Family

ID=55453266

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017010037A MX2017010037A (es) 2015-02-04 2016-02-02 Metodos de tratamiento de enfermedades inflamatorias.
MX2022006573A MX2022006573A (es) 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
MX2022006575A MX2022006575A (es) 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017010037A MX2017010037A (es) 2015-02-04 2016-02-02 Metodos de tratamiento de enfermedades inflamatorias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006575A MX2022006575A (es) 2015-02-04 2017-08-03 Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.

Country Status (15)

Country Link
US (1) US20160222102A1 (es)
EP (1) EP3253794A1 (es)
JP (5) JP6758304B2 (es)
KR (1) KR20170120616A (es)
CN (2) CN113559258A (es)
AU (2) AU2016215535B2 (es)
BR (1) BR112017014684A2 (es)
CA (1) CA2972995A1 (es)
CL (1) CL2017001960A1 (es)
EA (1) EA201791734A1 (es)
IL (2) IL307578A (es)
MX (3) MX2017010037A (es)
PH (1) PH12017501378A1 (es)
SG (2) SG10202103879YA (es)
WO (1) WO2016126638A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456740A1 (en) 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
SG11201701423RA (en) 2014-09-03 2017-03-30 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
SG10202103879YA (en) * 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
EP3560956A3 (en) * 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
JP2020500152A (ja) * 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
CN106778030B (zh) * 2017-01-10 2023-04-07 广州和康医疗技术有限公司 一种强直性脊柱炎病情监测管理系统及其监测管理方法
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
CN111378045B (zh) * 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
US20230303678A1 (en) * 2022-01-25 2023-09-28 Sun Pharmaceutical Industries Limited Methods for treatment of subjects with plaque psoriasis of the scalp

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
WO2007024846A2 (en) 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
PL1931710T3 (pl) 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
EP1971366B1 (en) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
EP3456740A1 (en) * 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
EP4039275A1 (en) * 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
WO2014004436A2 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EP3689369A1 (en) * 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
SG10202103879YA (en) * 2015-02-04 2021-05-28 Boehringer Ingelheim Int Methods of treating inflammatory diseases
JP7090014B2 (ja) * 2018-11-07 2022-06-23 株式会社ミツバ ロータ、モータ、ブラシレスワイパーモータ及びロータの製造方法

Also Published As

Publication number Publication date
KR20170120616A (ko) 2017-10-31
MX2022006575A (es) 2022-07-11
SG10202103879YA (en) 2021-05-28
CL2017001960A1 (es) 2018-04-20
NZ733136A (en) 2024-04-26
CN113559258A (zh) 2021-10-29
AU2016215535B2 (en) 2021-09-16
AU2016215535A1 (en) 2017-07-13
JP2020125338A (ja) 2020-08-20
JP2022081644A (ja) 2022-05-31
JP6758304B2 (ja) 2020-09-23
WO2016126638A1 (en) 2016-08-11
MX2017010037A (es) 2018-05-15
BR112017014684A2 (pt) 2018-01-09
JP7042297B2 (ja) 2022-03-25
CN107206081A (zh) 2017-09-26
JP2020125339A (ja) 2020-08-20
IL307578A (en) 2023-12-01
US20160222102A1 (en) 2016-08-04
IL253118A0 (en) 2017-08-31
JP2018505882A (ja) 2018-03-01
CA2972995A1 (en) 2016-08-11
SG11201705728RA (en) 2017-08-30
AU2021286378A1 (en) 2022-01-20
JP7042298B2 (ja) 2022-03-25
JP2020125340A (ja) 2020-08-20
PH12017501378A1 (en) 2018-01-08
EA201791734A1 (ru) 2018-01-31
EP3253794A1 (en) 2017-12-13
JP7044824B2 (ja) 2022-03-30

Similar Documents

Publication Publication Date Title
MX2022006573A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
ZA202000373B (en) Anti-cd47 antibodies and uses thereof
ZA201905488B (en) Tigit- and light-based chimeric proteins
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MD20170032A2 (ro) Anticorpi anti-TIGIT
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
PH12016501547A1 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
MX2024001617A (es) Composiciones biofarmaceuticas.
MY193175A (en) Apremilast pharmaceutical compositions
IL268007A (en) Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis
WO2015187521A3 (en) Anti-blys antibodies
PH12018501739A1 (en) Antibodies for il-17c
MX2023004315A (es) Anticuerpo neutralizante que se une a il-17a humana y a il-17f humana para usarse en el tratamiento de artritis.
MX2018012410A (es) Metodos para tratar enfermedades inflamatorias.
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
PH12017501872A1 (en) Methods of treating diseases
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.
MX2018002020A (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.